PMID- 31602237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 18
IP  - 5
DP  - 2019 Nov
TI  - Sphingolipid metabolism in type 2 diabetes and associated cardiovascular 
      complications.
PG  - 3603-3614
LID - 10.3892/etm.2019.7981 [doi]
AB  - Sphingolipid metabolism is dysregulated in type 2 diabetes mellitus (T2DM); 
      however, the focus of previous studies was mostly limited to ceramide (Cer), and 
      only few studies have investigated other metabolites, including sphingosine-1 
      phosphate (So1P). The present study aimed to examine the involvement of 8 major 
      sphingolipid metabolites, including Cer, glucosyl ceramide (GluCer), lactosyl 
      ceramide (LacCer), sphingomyelin (SM), sphinganine (Sa), So1P, sphingosine (So) 
      and sphinganine-1-phosphate (Sa1P), during the progression of T2DM, and to 
      evaluate the ability of serum sphingolipids to predict cases of diabetes with an 
      elevated risk of cardiovascular complications. Blood samples were obtained from 
      245 participants who were divided into 3 groups: Healthy controls, pre-diabetes 
      (pre-DM) and diagnosed diabetes. The 8 major sphingolipid metabolites were 
      measured by high-performance liquid chromatography-tandem mass spectrometry and 
      blood parameters were determined by routine laboratory assays for all subjects. 
      Among the sphingolipid metabolites, So1P was associated with sex and lean mass 
      index, but not with the body mass index. So1P was highest in healthy controls and 
      gradually decreased when the disease proceeded to pre-DM and T2DM. GluCer, SM, Sa 
      and So decreased in pre-DM and rose again in T2DM, graphically exhibiting a 'U' 
      shape change during the progression of diabetes. So1P and Sa were identified to 
      be significantly associated with cardiovascular complications by multivariate 
      logistic regression analysis. Receiver operating characteristic curve analysis 
      also suggested that So1P and Sa were able to indicate cardiovascular 
      complications in diabetic patients. Pre-DM and diabetes were significantly 
      associated with decreased So1P, SM, Sa and So, compared with the healthy 
      controls. So1P was correlated with the progression of T2DM, and was a predictor 
      of an elevated risk of cardiovascular complications among T2DM patients, along 
      with Sa. The present study was registered with ClinicalTrials.gov (no. 
      NCT02826759; April 2016).
CI  - Copyright (c) 2019, Spandidos Publications.
FAU - Sui, Jing
AU  - Sui J
AD  - Department of Endocrinology and International Medical Center, The First 
      Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. 
      China.
FAU - He, Mingqian
AU  - He M
AD  - Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
FAU - Zhao, Xinrui
AU  - Zhao X
AD  - Department of Immunology and Rheumatology, The Second Affiliated Hospital of 
      Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.
FAU - He, Yizhi
AU  - He Y
AD  - Department of Endocrinology, Xi'an No. 3 Hospital, Xi'an, Shaanxi 710018, P.R. 
      China.
FAU - Shi, Bingyin
AU  - Shi B
AD  - Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, Shaanxi 710061, P.R. China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02826759
PT  - Journal Article
DEP - 20190906
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6777336
OTO - NOTNLM
OT  - cardiovascular complications
OT  - sphingolipid metabolism
OT  - sphingosine-1-phosphate
OT  - type 2 diabetes
EDAT- 2019/10/12 06:00
MHDA- 2019/10/12 06:01
PMCR- 2019/09/06
CRDT- 2019/10/12 06:00
PHST- 2019/03/23 00:00 [received]
PHST- 2019/08/01 00:00 [accepted]
PHST- 2019/10/12 06:00 [entrez]
PHST- 2019/10/12 06:00 [pubmed]
PHST- 2019/10/12 06:01 [medline]
PHST- 2019/09/06 00:00 [pmc-release]
AID - ETM-0-0-7981 [pii]
AID - 10.3892/etm.2019.7981 [doi]
PST - ppublish
SO  - Exp Ther Med. 2019 Nov;18(5):3603-3614. doi: 10.3892/etm.2019.7981. Epub 2019 Sep 
      6.